Olpasiran Market Size, Forecast, and Emerging Insight - 2032

“Olpasiran Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about olpasiran for myocardial infarction in the seven major markets. A detailed picture of the olpasiran for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the olpasiran for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the olpasiran market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary

Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body’s production of apolipoprotein (a), a key component of Lp (a) that has been associated with an increased risk of cardiovascular events.

In November 2022, the company presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran in adults with elevated lipoprotein (a) [Lp (a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD) during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022, and simultaneously published in the New England Journal of Medicine. The company is currently conducting a Phase III trial with data expected by 2027.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the olpasiran description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on olpasiran regulatory milestones and other development activities have been provided in this report.
• The report also highlights the olpasiran research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around olpasiran.
• The report contains forecasted sales of olpasiran for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for olpasiran in myocardial infarction.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Olpasiran Analytical Perspective

In-depth Olpasiran Market Assessment

This report provides a detailed market assessment of olpasiran for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

Olpasiran Clinical Assessment

The report provides the clinical trials information of olpasiran for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence olpasiran dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to olpasiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of olpasiran in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of olpasiran from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the olpasiran in myocardial infarction.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of olpasiran?
• What is the clinical trial status of the study related to olpasiran in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the olpasiran development?
• What are the key designations that have been granted to olpasiran for myocardial infarction?
• What is the forecasted market scenario of olpasiran for myocardial infarction?
• What are the forecasted sales of olpasiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to olpasiran for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

This product will be delivered within 2 business days.